Clinical Trials Logo
  1. Home
  2. Cytomegalovirus Infections
  3. NCT02840825

Biochip for HCMV Detection in Breast Milk — VIRUMILK  

Cytomegalovirus Infections Clinical Trial

Official title:
Biochip for HCMV Detection in Breast Milk From Lactating Women of Preterm Infants Less Than 33 Weeks

Clinical Trial Summary

Human cytomegalovirus (HCMV) is the leading cause of neonatal viral infection and can have a significant impact on the neurosensory development of newborns and especially preterm infants. HCMV infection may result from maternal-fetal transmission during pregnancy or postnatal transmission. While congenital HCMV infection affects about 2-5% of very preterm infants, the risk of postnatal infection, particularly through breast milk, is much higher in this population (prevalence of about 20%). Many learned societies wonder about the interest to inactivate HCMV (by freezing or pasteurization) in breast milk in order to reduce or eliminate contamination of these children. However, freezing is relatively inefficient to reduce contamination and pasteurization drastically alters the nutritional quality of the milk. Therefore, a systematic preventive treatment of breast milk for very preterm infants is not currently recommended. An alternative approach could consist in detecting HCMV in breast milk to target at-risk situations. This detection can be performed by PCR but its cost and the time required to obtain the result prohibits its use for a mass detection. Currently, viral status of breast milk is not explored in practice and, depending on the health centers, breastfeeding is continued as such or milk is systematically inactivated.The main objective of VIRUMILK is to study the feasibility of the CMV detection in breast milk from lactating mothers with a biochip.The ultimate goal is to prevent postnatal HCMV infection of preterm newborns less than 33 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02840825
Study type Observational
Source Centre Hospitalier Universitaire de Besancon
Contact
Status Terminated
Phase
Start date March 8, 2016
Completion date September 29, 2021
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03950414 - A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients Phase 1
Recruiting NCT04690933 - AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Withdrawn NCT04936971 - Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response Phase 4
Recruiting NCT02671318 - Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Phase 4
Completed NCT01325636 - Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus Phase 1/Phase 2
Recruiting NCT00228202 - Genotyping of Cytomegalovirus From Patients in Israel N/A
Completed NCT00031421 - Neonatal CMV-Ganciclovir Follow-up Study N/A
Completed NCT00005496 - Inflammation, Infection, and Future Cardiovascular Risk N/A
Terminated NCT03262194 - Relevance of Gastric Aspirate in HCMV Detection
Completed NCT04478474 - Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
Recruiting NCT05370976 - Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. Phase 2
Active, not recruiting NCT02943057 - Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Phase 4
Completed NCT02538172 - Cell-mediated Immunity for Prevention of CMV Disease N/A
Completed NCT02642822 - The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University N/A
Completed NCT02134184 - The Influence of Chronic CMV Infection on Influenza Vaccine Responses Phase 4
Completed NCT00673868 - Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants Phase 1
Active, not recruiting NCT05089630 - A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults Phase 1/Phase 2
Not yet recruiting NCT06058858 - Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Active, not recruiting NCT04904614 - Letermovir Use in Heart Transplant Recipients Phase 4
Completed NCT01986010 - Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001) Phase 1